^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ZN-c5 (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of ZN-c5 in Subjects With Breast Cancer
Excerpt:
...- Estrogen Receptor (ER) positive disease...
Trial ID:
Source:
Title:
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
Excerpt:
...- Estrogen receptor positive disease...
Trial ID:
Less C2 evidence
Source:
Title:
ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
Published date:
10/09/2021
Excerpt:
Confirmed PRs have been observed in 2 subjects (at 150 and 300 mg QD, respectively), and 14/45 (31%) evaluable subjects have experienced clinical benefit (PR or SD ≥ 24 weeks). Five of the 14 subjects with long SD received prior fulvestrant. Median progression-free survival (PFS) was 3.8 months (95% CI: 3.2, 5.3). In this first-in-human study, ZN-c5 monotherapy was well tolerated and showed clinical benefit, including confirmed PRs, in subjects with advanced ER+/HER2- breast cancer.
Source:
Title:
A dose escalation study of the novel oral SERD-ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer
Published date:
11/17/2020
Excerpt:
ZN-c5 demonstrated a best response of stable disease (SD) in 10/15 subjects (66.5%), while progression of disease (PD) was reported in 5/15 subjects (33.5%)....the progression free survival (PFS) was a median of 3.8 months (95% [CI], 1.6 to 6.3)....ZN-c5 is very well-tolerated and has promising clinical activity in patients with ER+/HER2-negative advanced breast cancer...
